Carboplatin-pegylated liposomal doxorubicin-bevacizumab should be a new standard regimen for women with recurrent platinum-sensitive ovarian cancer suitable for antiangiogenic treatment, say the authors of a clinical trial.

The non-blinded trial, dubbed AGO-OVAR2.21, which included Australian patients, compared outcomes in 345 women randomised to carboplatin-pegylated liposomal doxorubicin-bevacizumab (the experimental group) with those for 337 women who received the standard regimen of carboplatin-gemcitibine-bevacizumab (control).

Participants (median age 62.5 years) in the trial, carried out between 2013 and 2015, all had recurrence six months or longer after using platinum-based therapy, 76% had residual tumour, 75% had high grade serous histology and 42% had used the antiangiogenic therapy, bevacizumab, before.

Median progression-free survival was 13.3 months in the experimental group, which was superior to the 11.6 months seen in the control group.